Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

Bangalore: Biocon has announced the appointment of Ekta Agarwal as the Interim Company Secretary and Compliance Officer ...

Syngene International, in collaboration with the Research and Innovation Circle of Hyderabad (RICH) and Biocon Foundation, has announced the launch of the third cohort of its flagship women-in-STEM ...

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

Prestige Estates Projects Ltd., Ashok Leyland Ltd., and Biocon Ltd. are three midcap stocks with 'buy' recommendations on ...

On July 9, even when the 90-day pause of Liberation Day ended, Nifty Pharma jumped by over 101 points before correcting.

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...

When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...

The pharma sector will be in focus on July 9, after Donald Trump said that he would make an announcement on pharmaceuticals ...

Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.